

studies are submitted to us with more than a dozen names on the title page, we insist that all persons listed there sign a statement that they fulfill *all* of these criteria. We believe that in every paper, each listed author must be able to take public responsibility for its content.

**Jerome P. Kassirer**  
*Editor-in-Chief,*

New England Journal of Medicine,  
10 Shattuck Street,  
Boston, MA 02115-6094, USA

#### References

1. S. Klahr *et al.*, *N. Engl. J. Med.* **330**, 877 (1994).
2. J. P. Kassirer and M. Angell, *ibid.* **325**, 1510 (1991).

### EPA and Biotechnology Regulation

The Policy Forum "A need to reinvent biotechnology regulation at the EPA" by Henry I. Miller (16 Dec., p. 1815) gravely misportrays an approach to reviewing biotechnology products of which I am proud.

The contention on which the Policy Forum is based, that the Environmental Protection Agency (EPA) regulates or singles out for special treatment products be-

cause they are created using recombinant DNA, is wrong. EPA has had a functioning program addressing biotechnology products under the Federal Insecticide, Fungicide and Rodenticide Act and the Toxic Substances Control Act since 1986 (1). That regulatory program focuses on identifying and minimizing risks to public health and the environment. Early indications are that many biotechnology products provide lower-risk agricultural and industrial approaches. For example, biological pesticides may present lower risks than do older chemical pesticides. In general, EPA wishes to promote development of environmentally safer products and technology. EPA's accomplishments in the biotechnology area show that it is achieving this goal.

EPA has an established record of bringing a range of biotechnology products through field testing to commercialization while safeguarding public health and the environment. At the same time, EPA's activities reassure the public concerning biotechnology products.

Readers who would like additional information are referred to documents in the public domain (2) that describe the EPA program.

**Lynn R. Goldman**  
*Assistant Administrator,*

Office of Prevention, Pesticides, and  
Toxic Substances,  
U.S. Environmental Protection Agency,  
Washington, DC 20460, USA

#### References and Notes

1. *Fed. Regist.* **51**, 23302 (26 June 1986).
2. *ibid.* **59**, 45600 (1 September 1994); *ibid.*, p. 45524 (23 November 1994); *ibid.*, p. 60495; *ibid.*, p. 60519; *ibid.*, p. 60535; *ibid.*, p. 60542; *ibid.*, p. 60545; most of these documents may be accessed through the Internet at [gopher.epa.gov](http://gopher.epa.gov) under the rules and regulations (Toxics Program) entries for 1 September 1994 and (Pesticide Program) 23 November 1994. Readers may also contact my office at 202-260-6900 for further information.

### Reading Disability, Attention-Deficit Hyperactivity Disorder, and the Immune System

The article "Quantitative trait locus for reading disability on chromosome 6" by Lon R. Cardon *et al.* (14 Oct., p. 276) describes a possible gene for a reading disability, dyslexia, localized to 6p21.3, a region within the human major histocompatibility complex (MHC). This finding accords closely with our observation (1) that

You've probably made a few generalizations about us Swedes—that's alright, we can take them. But making assumptions about the accuracy of your automated DNA sequencer can be costly. So demand proof.

ALFexpress™ provides you with speed, affordability and ease of use in giving you the highest accuracy from any automated DNA sequencer. More importantly, you can prove the accuracy of your data while your sequencer is in operation—and you can do it by yourself. How?

Let's start with the proof. ALFexpress lets you display called bases of both raw and processed data. Viewing raw data provides you with immediate visual confirmation of ALFexpress's reading accuracy—a must in demanding applications such as heterozygous detection.

Using single dye chemistry, ALFexpress eliminates spectral overlap and filtering problems and heightens the signal-to-noise ratio. Equipped with an outstanding base calling algorithm, you get accurate and reliable results. So with ALFexpress pumping

out clean, clear data you can check, you reduce operation time.

By generating 300 base pairs of accurate sequenced data in about an hour, you gain the type of speed that's difficult to match. As high-speed separations are equally important in fragment analysis, you can also separate between 150 and 200 base pairs in about 30 minutes on ALFexpress. Offering more than just sheer speed and accuracy, ALFexpress provides you with easy operating and working methods.

So easy that after only a two-hour introduction, six out of eight people with good lab experience—who had never used an automated DNA sequencer—got the kind of results that begin to prove this important point: you won't need a supervising technician in your lab with ALFexpress. And that was just the first test.

Why not arrange to take your own? To start, just call us at 1 (800) 526 3593 in North America, or +46 18 16 5011 from the rest of the world; and ask for a brochure. It will give you more facts about the entire ALFexpress package. That's right, facts—because the last thing anyone needs is more inaccurate documents.